HLS Therapeutics (TSX:HLS) reported that its cardiovascular drug, Vascepa, will be available in Canada on or about February 18, 2020. Vascepa was approved by Health Canada at the end of 2019. HLS noted that the approval...
Akcea Therapeutics (NASDAQ:AKCA) reported positive topline results from its Phase 2 study of AKCEA-ANGPTL3-LRx in patients with hypertriglyceridemia, Type 2 diabetes (T2D) and non-alcoholic fatty liver disease (NAFLD). ...
Ophthalmology, the peer-reviewed journal of the American Academy of Ophthalmology, published results of a Phase 3 clinical trial by Bausch Health Companies (NYSE, TSX:BHC) and Clearside Biomedical (NASDAQ:CLSD) of...
Imagin Medical (CSE:IME; OTCQB:IMEXF; Frankfurt & Stuttgart Symbol:DPD2) reported its 2019 i/Blue Imaging System development achievements and upcoming 2020 milestones. “2019 was a momentous year for the Company as...
The FDA granted fast track designation for Genprex’s (NASDAQ:GNPX) Oncoprex immunogene therapy in combination with osimertinib for the treatment of non-small cell lung cancer (NSCLC) patients with epidermal growth...
Aldeyra Therapeutics (NASDAQ:ALDX) enrolled the first patient in its Phase 3 INVIGORATE trial of topical ocular reproxalap for the treatment of allergic conjunctivitis. The trial will enroll some 120 patients to assess...
Tyme Technologies (NASDAQ:TYME) dosed the first patient in its HopES Phase 2 trial evaluating SM-88 for the treatment of high-risk sarcomas. SM-88, or racemetyrosine, is a modified tyrosine derivative designed to...
Kala Pharmaceuticals (NASDAQ:KALA) completed enrollment in its STRIDE 3 Phase 3 clinical trial of EYSUVIS for the short-term treatment of dry eye disease. The trial’s inclusion/exclusion criteria have been modified from...
The FDA granted fast track designation for Novavax’s (NASDAQ:NVAX) NanoFlu, a seasonal influenza vaccine candidate, in adults 65 years of age and older. “We believe that NanoFlu will offer an innovative improvement...
Mesoblast (NASDAQ:MESO; ASX:MSB) plans to file the final module of the rolling biologics license application for Ryoncil with the FDA in January and then request a priority review of the BLA under the product...
Mereo BioPharma (NASDAQ:MREO) reported additional data from its Phase 2b ASTEROID clinical study of setrusumab in adults with Type 1, 3, and 4 osteogenesis imperfecta (OI). OI, also known as brittle bone disease, is...
BioLineRx (NASDAQ:BLRX) received European Medicines Agency orphan drug designation (ODD) for motixafortide for the treatment of pancreatic cancer. Motixafortide is a short synthetic peptide designed to target CXCR4, a...
The FDA has granted 510(k) clearance for Biocardia’s (OTCQB:BCDA) Morph DNA deflectable guide catheter. The catheter is designed to enhance procedural control of therapeutic catheters, particularly Biocardia’s Helix...
Closely-held Interface Biologics launched Ripple Therapeutics, a privately held, clinical stage developer of novel drugs. The launch comes four months after Interface sold its Endexo surface modification business to...
Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine implant, a novel six-month maintenance treatment for opioid use disorder (OUD), will be included on the Federal Supply Schedule (FSS) beginning on January 15, 2020. The...
Profound Medical (NASDAQ:PROF; TSX:PRN) signed its first U.S. multi-site imaging center agreement for TULSA-PRO with RadNet (NASDAQ:RDNT), a leading provider of fixed-site outpatient diagnostic imaging services with a...
Troutman Sanders and Pepper Hamilton agreed to merge, effective on April 1, creating a new 1,100-lawyer giant with offices in 23 locations, including eight of the 10 top U.S. markets. The new firm will be known as...
BriaCell Therapeutics (TSXV:BCT; OTCQB:BCTXD) identified a new group of patients with high levels of clinical benefit in response to its immunotherapy, and in combination with checkpoint inhibitors. After a reanalysis...
Hepion Pharmaceuticals (NASDAQ:HEPA) is slated to present a poster at the upcoming NASH-TAG 2020 conference. The presentation will provide details of four nonclinical studies demonstrating that CRV431 decreases liver...
Imagin Medical (CSE:IME; OTCQB:IMEXF; Frankfurt & Stuttgart Symbol:DPD2) completed design verification of its i/Blue Imaging System functional unit on schedule. i/Blue is based on advanced optics and light sensors...
Apellis Pharmaceuticals (NASDAQ:APLS) reported positive topline results from its Phase 3 study evaluating pegcetacoplan for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Pegcetacoplan met the study’s...
Hepion Pharmaceuticals’ (NASDAQ:HEPA) comprehensive review of studies on the role of cyclophilins in non-alcoholic steatohepatitis (NASH) and NASH-related liver disease has been published in peer-reviewed journal...